Published in

BMJ Publishing Group, BMJ Open, 11(12), p. e062463, 2022

DOI: 10.1136/bmjopen-2022-062463

Links

Tools

Export citation

Search in Google Scholar

Vocal biomarker predicts fatigue in people with COVID-19: results from the prospective Predi-COVID cohort study

This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Green circle
Postprint: archiving allowed
Green circle
Published version: archiving allowed
Data provided by SHERPA/RoMEO

Abstract

ObjectiveTo develop a vocal biomarker for fatigue monitoring in people with COVID-19.DesignProspective cohort study.SettingPredi-COVID data between May 2020 and May 2021.ParticipantsA total of 1772 voice recordings were used to train an AI-based algorithm to predict fatigue, stratified by gender and smartphone’s operating system (Android/iOS). The recordings were collected from 296 participants tracked for 2 weeks following SARS-CoV-2 infection.Primary and secondary outcome measuresFour machine learning algorithms (logistic regression, k-nearest neighbours, support vector machine and soft voting classifier) were used to train and derive the fatigue vocal biomarker. The models were evaluated based on the following metrics: area under the curve (AUC), accuracy, F1-score, precision and recall. The Brier score was also used to evaluate the models’ calibrations.ResultsThe final study population included 56% of women and had a mean (±SD) age of 40 (±13) years. Women were more likely to report fatigue (p<0.001). We developed four models for Android female, Android male, iOS female and iOS male users with a weighted AUC of 86%, 82%, 79%, 85% and a mean Brier Score of 0.15, 0.12, 0.17, 0.12, respectively. The vocal biomarker derived from the prediction models successfully discriminated COVID-19 participants with and without fatigue.ConclusionsThis study demonstrates the feasibility of identifying and remotely monitoring fatigue thanks to voice. Vocal biomarkers, digitally integrated into telemedicine technologies, are expected to improve the monitoring of people with COVID-19 or Long-COVID.Trial registration numberNCT04380987.